Skip to main content
. 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799

Figure 3.

Figure 3

FLT3–ITD AR cutoff point with prognostic impact. Cutoff point selection using maximal log-rank statistics. Optimal cutoff point for AR by maximally selected log-rank statistics in intensively treated FLT–ITD-positive AML cases. Maximally selected log-rank statistics performed for the continuum of AR to test for a potential cutoff point by separating 2 groups with different survival distributions. AR is shown on the x-axis, and the corresponding standardized log-rank statistic is shown on the y-axis. The estimated cutoff point was 0.44, with an M statistic of 3.14 (a). The vertical dashed line represents the optimal cutoff point for AR evident on maximally selected log-rank statistics and corresponding M statistics. Impact on prognosis of cutoff point on OS for patients with AML consolidated with CTX/auto-HSCT (b) or with allo-HSCT (c). Impact on prognosis of cutoff point on RFS for patients with AML consolidated with CTX/auto-HSCT (d) or with allo-HSCT (e). In the groups consolidated with CTX/auto-HSCT, the estimated median OS in group with FLT3–ITD AR > 0.44 was 8.7 months (7.0–10.4) vs. 15.6 months (14.3–17.0) for group with FLT3–ITD AR< or = 0.44 (p < 0.001) (b,d). In the groups consolidated with allo-HSCT, the estimated median OS in the group with FLT3–ITD AR > 0.44 was 142.7 months (0–330.5) vs. 94.4 months (53.5–135.4) for the group with FLT3–ITD AR < or = 0.44 (p = NS) (c,e).